Skip to content

Maria Teresa Colomina

3 papers in the library · 66 citations · publishing 2022-2024

Papers

Sort Most recent Most cited

A transcriptomic analysis in mice following a single dose of ibogaine identifies new potential therapeutic targets.

Translational Psychiatry January 19, 2024 Judit Biosca-Brull, Genís Ona, Lineth Alarcón-franco et al. 5 citations

Ibogaine (IBO) is an atypical psychedelic with a complex mechanism of action. To date, the mechanisms that may underlie its anti-addictive effects are still not defined. This study aims to identify changes in gene expression induced by a single oral dose of IBO in the cortex of mice by means of a transcriptomic analysis for the first time. Our results showed significant alterations in gene...

Main targets of ibogaine and noribogaine associated with its putative anti-addictive effects: A mechanistic overview.

Journal of psychopharmacology (Oxford, England) December 1, 2023 Genís Ona, Ingrid Reverte, Giordano N. Rossi et al. 20 citations

There is a growing interest in studying ibogaine (IBO) as a potential treatment for substance use disorders (SUDs). However, its clinical use has been hindered for mainly two reasons: First, the lack of randomized, controlled studies informing about its safety and efficacy. And second, IBO's mechanisms of action remain obscure. It has been challenging to elucidate a predominant mechanism of...

The adverse events of ibogaine in humans: an updated systematic review of the literature (2015-2020).

Psychopharmacology June 1, 2022 Genís Ona, Juliana Mendes Rocha, José Carlos Bouso et al. 41 citations

Ibogaine is the main alkaloid of the African shrub Tabernanthe iboga. It produces hallucinogenic and psychostimulant effects, but it is currently known for the anti-addictive properties. Despite the potential therapeutic effects, several cases of fatalities and serious adverse events related to ibogaine/noribogaine use can be found in the literature. Most studies consist in case reports or were...